17β-雌二醇
17β-雌二醇凝胶与补佳乐在冻融胚胎复苏移植临床观察

世界最新医学信息文摘 2018年 第18卷 第32期101投稿邮箱:sjzxyx88@·药物与临床·17β-雌二醇凝胶与补佳乐在冻融胚胎复苏移植临床观察马淑芳(武汉康健妇婴医院,湖北 武汉 430000)0 引言FET 作为目前辅助生殖技术的重要组成部分,提高了体外受精周期累积妊娠率,避免了OHSS 高风险和高孕酮引发的新鲜胚胎妊娠率低的不足。
目前武汉康健妇婴医院患者中因OHSS 高风险、高孕酮导致新鲜胚胎全陪冷冻的患者首次移植周期,冻融胚胎妊娠率和新鲜胚无明显差异[1]。
FET 中常用的内膜准备药物,有戊酸雌二醇、17β-雌二醇凝胶、17β-雌二醇片。
观察17β-雌二醇凝胶与戊酸雌二醇的临床疗效。
1 资料与方法1.1 资料。
回顾性分析2016年1月至2017年8月就诊于我院生殖中心行TET 的不孕妇女,共246位患者。
纳入标准:首次冻融胚胎复苏移植的患者,全胚冷冻原因为OHSS 高风险和孕酮大于2 ng/ml 。
年龄19-38岁,平均年龄(30.58±5.14)岁,双方染色体正常,排除子宫畸形,子宫粘连,输卵管积水因素。
1.2 方法1.2.1 激素替代周期准备内膜:A 组患者月经第3天17β-雌二醇凝胶5 g ,bid ,涂抹于皮肤更容易吸收的地方,如胳膊、臂部上部等,除外乳房和粘膜区,8天监测子宫内膜厚度,<8 mm 继续原剂量外用3天后观察内膜情况至内膜≥8 mm ; B 组患者月经第3天,超声正常,孕酮P<1 ng/ml ,口服戊酸雌二醇2 mg ,4 mg ,6 mg ,3天递增。
9天B 超监测子宫内膜厚度,内膜<8 mm 时继续口服6mg 补佳乐,3天监测内膜直至≥8 mm 。
1.2.2 转型内膜:A ,B 两组患者子宫内膜≥8并检查血孕酮浓度,孕酮<1 ng/ml ,给予转型,黄体酮60 mg ,3天后移植两枚D3卵裂胚胎,移植后移植后28天检查彩超,可见孕囊为临床妊娠。
17β-雌二醇保护6-羟基多巴胺损伤的多巴胺能神经细胞的作用机制

rn o yit cnrl ru wi o t d iga yrae t, nep r na cnrl ru pu 0  ̄ lL6O a d ml oa o to go p( t u dn n gn) a ei tlo to go p( ls 0/ / - HDA)ad n h a e x me 2 mo n
CHI S OURNA NE E J L 0F ANAT 0MY L3 . 0 2 Vo 5No 12 1
解剖学杂志
21 0 2年第 3 卷第 1 5 期
1 p雌 二醇 保 护 6羟 基 多 巴胺 损伤 的 多 巴胺 能神 经 细胞 的作 用 机 制 7一 一
刘 亚 萍 王 晓舟 王 萌。 史子 啸。 徐夏 红。 王 婷。 高殿 帅。 △
p m ie a n .M eh d :Th -一 a - l l D asweed c pttd u d rsei o dt n ,a d te h l e r iie to s e23 d y odmaeS r t r ea i e n e trl c n ii s n h n t esi sweedvd d a e o c
度为 20 ̄ lL 、7- 2 a - D 0 mo )1 ̄E 组( n OH A后再加浓度为 1 _ mo L 1 ̄E ) / 6 0 。 l 7 2 。免疫荧 光显色检测脑 片中酪氨酸羟化酶( 。 / TH) 的表达 ; 印迹检测脑 片中 T 免疫 H、pA t c 2的表达。结果 :7 2 - k、Bl - 1 ̄E 组中 T 阳性神经细胞数量 3. 3 . 1 H 2 8 ±36 与实验对照 组 1. 7 . 2 比, 6 6 ±2 4 相 差异有统计学意义。免疫印迹结果显示 , 与空 白对照组相 比, 实验对照组 中TH、 磷酸化( )A t B - P一k 和 d2
雌二醇含量的测定方法

雌二醇含量的测定方法
雌二醇(estradiol-17β,E2)是生物活性最强的一种雌激素,主要由卵巢分泌,具有促进女性生殖上皮、乳腺、子宫、长骨的生长及第二性征的发育,以及参与脂代谢、调节血管平滑肌和内皮细胞的功能等。
其含量测定方法有以下几种:
-酶联免疫吸附法:利用抗原抗体反应的高度特异性和酶的高效催化作用,通过酶标记物的颜色变化或发光强度,对待测样本中雌二醇的含量进行定性或定量分析。
-化学发光免疫分析法:利用化学发光物质标记抗原或抗体,通过抗原抗体反应后产生的化学发光信号,对待测样本中雌二醇的含量进行检测。
-色谱法:利用不同物质在色谱柱上的保留时间和峰面积的差异,对待测样本中雌二醇的含量进行分离和检测。
-荧光免疫分析法:利用荧光物质标记抗原或抗体,通过抗原抗体反应后产生的荧光信号,对待测样本中雌二醇的含量进行检测。
不同的测定方法具有不同的优缺点和适用范围,具体选择哪种方法取决于实验目的、样本类型和实验条件等因素。
17β-雌二醇乙酸纤维分子印迹复合膜的制备及性能研究

3 ttK y aoa r r e ni n e t c ne Xa e n e i , i n Fj n3 10 , hn ) . a e brt oMai v om na Si c, i nU i r t Xa , ui , 0 5 C i S e L o f y nE r l e m vs y me a 6 a
b sn o o s c l l s c tt mb a e a u p r h e e t e b n ig p o e t s a d s p a in c p ct ft e y u ig p r u e l o e a eae me r n s s p o .T e s lc i i d n r p r e u t v i n e a t a ai o r o y h
2 1 ,0 6 0 12 ( )
福建分析测试
F j n nls &Tsn ui a i a A y s et g i
1 雌二醇 乙酸纤维分子印迹复合膜的制备及性能研究 p一 7
刘 美华 邱 彬 陈 国南 陈 曦 , , , , 。
(. 1 福建师范大学福清分校 , 福建 福清 3 0 0 5 3 0; 2 福州大学 食品安全分析与检测教育部重点实验室 , . 化学化工学院 , 福建
1 【 e i ye t do d t eme rn s K e a etmp ae 70 - t n lsr il h a n a mb a eWa we k rt n t h h h e lt.
Ke wo d y r s:c l ls ctt mba e,1 —E ta il moeual r tdc mp st mba e el o eae eme rn u a 7B srdo , lc l yi i e o oi me r . r mp n e n
心肌内注射17β-雌二醇纳米粒对大鼠心梗的修复作用

心肌内注射17β-雌二醇纳米粒对大鼠心梗的修复作用1刘伟强1,陈玉成1,熊素彬2,曾智1▲,金鑫1,王斌1,王浩宇11.四川大学华西医院心内科,成都(610041)2.浙江工业大学药学院,杭州(310032)E-mail:chenyucheng2003@摘要:目的探讨心肌内局部肌注17β-雌二醇纳米粒对大鼠心梗后血管生成、梗死面积、死亡率的影响。
方法以聚乳酸和乙醇酸共聚物(poly-dl-lactic-CO-glycolic acid,PLGA)纳米粒为载体制备17β-雌二醇纳米粒,评价其理化性质及体内、外药物释放参数.制备去卵巢大鼠心梗模型,随机分为实验组(在心梗边缘区注射17β-雌二醇纳米粒4mg/100g,n=20),实验对照组(在心梗边缘区注射空白纳米粒4mg/100g,n=20 ),空白对照组(仅制备去卵巢心梗模型,n=20).1月后免疫组化法检测心梗边缘区毛细血管密度(microvascular density,MVD) 及eNOS累积光密度(IOD)值,测量梗死面积。
结果体外释放参数显示,1月时17β-雌二醇累积释放率已接近100%,体内释放曲线显示心肌内注射1月后血清仍保持较高药物浓度(345.480 ±8.906pg/ml).心梗1月后与对照组相比,实验组免疫组化法显示梗死边缘区毛细血管密度增加(P<0.05),eNOS蛋白IOD值增多(P<0.05),梗死面积减小(P<0.05),死亡率无升高(P=1.000)。
结论心肌内局部注射17β-雌二醇纳米粒可有效促进大鼠梗死后心肌毛细血管生成,减少心梗面积,不增加死亡率,对心梗有较好的修复作用.关键词:雌二醇;纳米粒;血管生成;梗死面积冠心病是当今妇女最重要的死亡原因之一,虽已有药物溶栓、冠状动脉成型术(PTCA 和支架植入术)及冠状动脉旁路移植术等常规治疗方法,但对部分患者(如晚期冠心病等),仍缺乏有效的手段.有研究表明皮下注射17β-雌二醇具有较好的促心肌血管生成作用[1,2],但临床随机对照试验却发现在雌激素替代治疗中带来更多的乳腺癌、静脉血栓、脑卒中等发病率,甚至抵消了其对心血管的获益[3],改变用药方式(局部用药)可能是较好的应对策略.但其在心脏局部应用是否能有效促心肌毛细血管生目前尚不清楚.同时雌激素替代治疗对梗死面积的影响也有争议[4,5],且可能增加死亡率[5],消弱了其在冠心病中的应用价值.我们利用纳米技术制备具有良好缓释作用和组织穿透能力的17β-雌二醇纳米粒,心肌内局部注射,探讨其对大鼠心梗后心肌毛细血管生成及梗死面积、死亡率的影响.。
17β-雌二醇联合苯并芘异常激活人肺腺癌A549细胞中AHR

17β-雌二醇联合苯并芘异常激活人肺腺癌A549细胞中AHR/PD -L1轴*冯昊1, 曹伯雄1, 昝自亮1, 贺泽民1, 黄浩1, 皇改改2, 魏强1△(1成都市双流区第一人民医院胸外科,四川 成都 610000;2成都市双流区第一人民医院医学检验科,四川 成都 610000)[摘要] 目的:探讨17β-雌二醇(17β-estradiol , E 2)和苯并芘(benzopyrene , BaP )对人肺腺癌A549细胞程序性死亡配体1(programmed death ligand 1, PD -L1)表达的影响及其潜在分子机制。
方法:分别选用浓度梯度为1~1 000 nmol/L 的E 2和浓度梯度为0.008~5 μmol/L 的BaP 处理A549细胞,筛选出最适浓度;实验分为对照组、E 2组、BaP 和E 2+BaP 组,每组实验重复3次。
RT -qPCR 检测PD -L1的mRNA 水平;Western blot 检测PD -L1、芳香烃受体(aryl hydrocarbon receptor , AHR )和缺氧诱导因子1α(hypoxia -inducible factor -1α, HIF -1α)表达水平,以及蛋白激酶B (protein kinase B , PKB/AKT )和细胞外信号调节激酶1/2(extracellular signal -regulated kinase 1/2, ERK1/2)的磷酸化水平。
分别加入AKT 特异性抑制剂LY294002和ERK1/2特异性抑制剂PD98059进行反向验证,观察PD -L1表达的变化。
结果:与E 2组和BaP 组相比,E 2+BaP 组A549细胞中PD -L1的mRNA 和蛋白表达水平均显著上调(P <0.05);AHR 、HIF -1α、p -AKT 和p -ERK1/2蛋白水平均显著高于其他各组(P <0.05);LY294002和PD98059能够逆转E 2+BaP 对A549细胞PD -L1表达的上调作用(P <0.05)。
一种基于适配体传感器的17β-雌二醇定量分析方法
一种基于适配体传感器的17β-雌二醇定量分析方法作者:史学丽,高辉,周永红,赵伟来源:《河北工业科技》2021年第05期摘要:為了灵敏、特异地测定牛奶中17β-雌二醇(E2)的含量,解决传统方法测定时因原位激发导致的荧光背景干扰、样品预处理复杂等问题,基于荧光共振能量转移(FRET)原理,结合适配体与靶标的特异性识别,建立一种基于荧光适配体传感器的E2定量分析方法。
采用水热合成法制备铕(Eu3+)掺杂的镓酸锌长余辉纳米粒子,并将E2适配体修饰到纳米粒子(PLNP)上,形成复合物(PLNP-Aptamer)。
以PLNP-Aptamer为能量供体,以二硫化钼纳米片为能量受体,根据荧光强度与靶标17β-雌二醇之间的线性关系实现对E2的检测,并对检测条件进行优化。
结果表明,当PLNP-Aptamer、二硫化钼的质量浓度分别为0.1,0.8mg/mL,E2与适配体的孵育时间为20 min,pH值为7.0时,雌二醇的线性检测范围为0.6~80 ng/mL,检出限为0.4 ng/mL。
通过加标回收实验,证明检测体系对17β-雌二醇具有显著的选择性,可用于实际样品的检测。
所提方法解决了样品预处理复杂耗时,乳基质荧光干扰等问题,可为基层卫生监督工作提供一种简单、高效、成本低廉的雌激素检测方法,对其他环境雌激素的检测也具有参考价值和借鉴意义。
关键词:应用生物化学;荧光;纳米传感器;二硫化钼;镓酸锌中图分类号:R926文献标识码:ADOI: 10.7535/hbgykj.2021yx05005A quantitative analysis method for 17β-estradiol based on aptasensorSHI Xueli1,GAO Hui1,ZHOU Yonghong1,ZHAO Wei2(1.Shijiazhuang Maternity and Child Healthcare Hospital,Shijiazhuang,Hebei 050051,China;2.Shijiazhuang Center for Disease Control and Prevention,Shijiazhuang,Hebei 050019,China)Abstract:In order to determine the content of 17β-estradiol (E2) in milk sensitively and specifically,and solve the problems such as the interference of fluorescence background caused by in-situ excitation and the complexity of sample pretreatment in the traditional method,a quantitative analysis method for 17β-estradiol based on fluorescence aptasensor was constructed on grounds of the fluorescence resonance energy transfer (FRET),combined with the specificity of the aptamer and target recognition.Persistent luminescence nanoparticles (PLNP) doped with Eu3+ were prepared by the hydrothermal method and modified with E2 aptamers onto PLNP to form the coupling complex PLNP-Aptamer.In this method,PLNP-Aptamer was used as energy donor.MoS2 was used as the acceptor.According to the linear relationship between phosphorescent intensity and target E2,the content of E2 was detected,and the detection conditions were optimized.The results show that when the concentrations of PLNP-Aptamer and MoS2 are 0.1 mg/mL and 0.8 mg/mL respectively,the reaction time of E2 and aptamer is 20 min,pH is 7.0,the linear detection scope of E2 concentration is from 0.6 ng/mL to 80 ng/mL and the detection limit is 0.4 ng/mL.The adding standard recovery experiment proves that the detection system has high specificity to E2,and can realize quantitative detection of E2 in actual samples.The method provides a simple,efficient and low-cost estrogen detection method for grass-roots health supervision by solving the problem of the complicated time-consuming of sample pretreatment and avoiding the fluorescence interference of milk matrix.It also provides a reference for other environmental estrogens detection.Keywords:applied biochemistry;fluorescence;nanosensor;MoS2;ZnGa2O417β-雌二醇(17β-estradiol,E2)是一种具有内分泌干扰效应的内源性雌激素,过量摄入可严重干扰内分泌系统[1-2]。
雌二醇正常值
雌二醇正常值雌二醇是一种重要的女性激素,它在女性身体中发挥着重要的作用。
了解雌二醇的正常值范围对于评估女性的健康状态非常重要。
本文将介绍雌二醇的定义、功能以及正常值范围。
1. 雌二醇的定义与功能雌二醇是一种雌激素,其化学名称为17β-雌二醇。
人体中主要由卵巢分泌,也由其他组织如胎盘、肾上腺、脂肪组织等产生。
雌二醇在女性身体中扮演着重要的角色,其功能包括:•促进女性第二性征的发育,如乳房生长、骨骼生长等。
•维护女性生殖系统的正常功能,包括月经周期和子宫内膜的生长。
•参与调节女性生理周期和妊娠过程。
2. 雌二醇的正常值范围雌二醇的正常值范围可以根据不同的生理状态和年龄段进行区分。
以下是雌二醇的正常值参考范围:•非孕妇的雌二醇正常范围:30-400 pg/mL•孕妇的雌二醇正常范围:–孕早期:100-1000 pg/mL–孕中期:200-6000 pg/mL–孕晚期:1000-18000 pg/mL•绝经期前后的妇女雌二醇正常范围:10-60 pg/mL•青春期女性的雌二醇正常范围:20-400 pg/mL需要注意的是,不同实验室的测试方法和单位可能会有所差异,因此实际的正常值范围可能会有一定的变异。
3. 影响雌二醇水平的因素雌二醇的水平可能会受到多种因素的影响。
以下是一些可能影响雌二醇水平的因素:•年龄:女性的雌二醇水平随着年龄的增长而逐渐下降,尤其是在绝经期后。
•孕妇:孕妇的雌二醇水平通常会显著增加,特别是在妊娠的中后期。
•药物:某些药物,如某些抗癫痫药物和雌激素类药物,可能会影响雌二醇的水平。
•肥胖:肥胖女性通常有更高的雌二醇水平,因为脂肪组织可以产生一定量的雌激素。
4. 异常雌二醇水平的可能意义异常的雌二醇水平可能与一些健康问题相关。
以下是一些可能的意义:•高雌二醇水平可能与多囊卵巢综合征(PCOS)相关,PCOS是一种常见的女性生殖系统疾病。
•低雌二醇水平可能与卵巢功能减退、绝经和骨质疏松等问题相关。
雌二醇正常值
雌二醇正常值人体内的激素水平对身体的正常功能和健康起着至关重要的作用。
雌二醇是女性体内主要的雌激素之一,对女性的性征发育、月经周期和生殖健康等方面起着重要的调控作用。
了解雌二醇的正常值范围对于判断一个女性的性激素平衡和健康状态至关重要。
本文将详细介绍雌二醇的正常值范围以及与之相关的信息。
一、雌二醇简介雌二醇,化学名称为17-β-雌二醇,是人体内最重要的雌激素之一。
在女性体内,卵巢是主要的雌二醇产生器官,同时其也在男性体内存在,但水平较低。
雌二醇在女性的性激素平衡、生育能力以及骨骼健康等方面发挥着至关重要的作用。
对于女性来说,了解雌二醇正常值的范围非常重要,有助于判断她们的性激素水平是否处于正常状态。
二、雌二醇的正常值范围雌二醇的正常值会因为人体的生理状况、年龄和周期等因素而有所变化。
一般来说,雌二醇的正常浓度范围为单位。
以下是不同阶段女性的雌二醇正常参考范围:1. 孩童和青春期前:在女性的儿童和青春期前,雌二醇的水平较低。
一般来说,雌二醇的正常浓度范围为单位。
2. 青春期:在女性的青春期,卵巢开始分泌雌二醇,促使乳房、生殖器和骨骼的发育。
此时,雌二醇的正常浓度范围为单位。
3. 妊娠期:在女性怀孕期间,雌二醇的水平显著上升。
这是因为胎儿和胎盘也会分泌雌激素。
雌二醇的正常浓度范围为单位。
4. 绝经期前:女性进入绝经期前,卵巢开始逐渐减少雌二醇的分泌。
正常浓度范围为单位。
5. 绝经期:女性进入绝经期后,卵巢停止雌二醇的分泌。
此时,雌二醇的正常浓度范围较低,一般为单位。
三、影响雌二醇水平的因素除了生理年龄和生理状况外,一些外界因素也可能会对雌二醇水平产生影响。
以下是一些常见的与雌二醇水平相关的因素:1. 药物和治疗:某些药物,如口服避孕药、激素替代疗法和抗癌药物等,可能会影响雌二醇水平。
在进行实验室测试之前,及时向医生告知正在使用的药物和治疗方式非常重要。
2. 营养和饮食:饮食对于雌二醇水平的影响是复杂的。
17―β―雌二醇对猪卵母细胞体外成熟及体外受精胚的影响
17―β―雌二醇对猪卵母细胞体外成熟及体外受精胚的影响摘要:为了观察17-β-雌二醇对猪卵母细胞体外成熟及体外受精胚的影响,选用屠体卵巢上的卵母细胞为试验材料,将其分为4组,分别在培养基中添加0、25、50、75 μmol/L 17-β-雌二醇,体外成熟培养时间为36~44 h,受精胚培养时间为9 d。
结果表明,在培养基中分别添加17-β-雌二醇0、25、50、75 μmol/L时猪卵母细胞体外成熟率分别为58.5%、67.1%、80.9%、64.5%,卵裂率分别为51.2%、56.5%、63.5%、59.2%,囊胚形成率分别为16.7%、24.2%、19.5%、24.0%。
结果显示在培养基中添加50 μmol/L 17-β-雌二醇可提高猪卵母细胞体外成熟率至80.9%,提高体外受精胚的卵裂率至63.5%,但囊胚形成率以添加量为25 μmol/L的组最高,说明添加17-β-雌二醇可提高猪卵母细胞成熟率、卵裂率以及囊胚率。
关键词:17-β-雌二醇;卵母细胞;体外成熟;体外受精;胚胎培养中图分类号:S828.3 文献标识码:A 文章编号:0439-8114(2015)22-5660-02Abstract:For observing the effect of 17-β-E2 on theporcine oocytes maturation and fertilized embryos’development in vitro,the porcine oocytes collected from prepubertal gilts’ovaries were cultured in maturation medium which added different concentration 17-β-estrodiol (0、25、50、75 μmol/L)for 36~44 hours. The fertilized eggs were cultured for 9 days. The results showed that the maturation rate of each addition was 58.5%,67.1%,80.9%,64.5%,respectively. The cleavage rate was 51.2%,56.5%,63.5%,59.2%,respectively,and the blastocyst rate was 16.7%,24.2%,19.5% and 24.0%,respectively. It indicated that the addition of 17-β-estrodiol could improve maturation rate,cleavage rate and blastocyst rate,and the maturation rate & cleavage rate of 50 μmol/L addition were higher than the other 3 groups,but the blastocyst rate of 25 μmol/L addition was higher than the other groups.Key words:17-β-estrodiol;porcine oocytes;in vitro maturation;in vitro fertilization;embryo culture自Mattiol等[1]用屠体的卵母细胞获试管猪以来,卵母细胞的体外成熟培养已经取得了较大的进展[2]。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
17-Estradiol promotes the up-regulation of SR-BII in HepG2 cells and in rat liversGregory A. Graf, Kathy L. Roswell, and Eric J. Smart1University of Kentucky Medical School, Department of Physiology, Lexington, KY 40536Abstract The scavenger receptor class B type I (SR-BI) binds to HDL and mediates the selective uptake of cholesterol esters from HDL to cells. SR-BII is an alternatively spliced product of the SR-BI gene that only differs in the C-terminal cytoplasmic domain. Previous studies with male mice demonstrated that SR-BII comprises about 12% of the total SR-BI/SR-BII present in liver. In the current studies we used a liver cell line, HepG2, and a rat estrogen replacement model to examine the effects of estrogen on the expression of SR-BII. HepG2 cells express SR-BI but not SR-BII. SR-BI/SR-BII-blocking antibodies dem-onstrated that HepG2 cells selectively internalize cholesterol esters in a SR-BI-dependent manner. Incubation of HepG2 cells with 10 pM of 17-estradiol for 12 h eliminated the ex-pression of SR-BI and promoted the up-regulation of SR-BII. Radiolabeled HDL-binding studies demonstrated that 17-estradiol increased the number of HDL binding sites by 3-fold in HepG2 cells. However, 17-estradiol-treated cell internal-ized approximately 25% less cholesterol ester than vehicle-only-treated cells. The livers obtained from male rats and ovariec-tomized female rats contained SR-BI and a small amount of SR-BII. In contrast, the livers obtained from intact female rats and ovariectomized female rats receiving estrogen replace-ment contained SR-BII and a small amount of SR-BI. The amount of SR-BI and SR-BII in adrenal tissue was not affected by any of the experimental treatments. We conclude that es-trogen up-regulates SR-BII in HepG2 cells and rat liver.—Graf G. A., K. L. Roswell, and E. J. Smart. 17-Estradiol promotes the up-regulation of SR-BII in HepG2 cells and in rat livers.J. Lipid Res.2001. 42: 1444–1449.Supplementary key words HDL • cholesterol ester • scavenger receptor •selective uptakeThe scavenger receptor class B type I (SR-BI) is a physio-logical HDL receptor involved in the selective uptake of HDL cholesterol ester (1). Selective uptake refers to the internalization of HDL cholesterol esters without the in-ternalization of HDL apoproteins (2, 3). Webb et al. (4, 5) described a splice variant of SR-BI called SR-BII that is ex-pressed in rodents and humans. The amino acid se-quences of SR-BI and SR-BII are identical except for the C-terminal cytoplasmic tail (4, 5). Despite the remarkable amino acid similarity to SR-BI, SR-BII is approximately 4-fold less efficient at selective cholesterol ester uptake than SR-BI. SR-BII accounts for only about 12% of the total SR-BI/SR-BII found in mouse liver even though the mRNA for SR-BII comprises about 40% of the total SR-BI/SR-BII mRNA in liver (4, 5). It is unclear if SR-BII plays a signifi-cant role in selective cholesterol ester uptake in vivo.The expression of SR-BI appears to be coordinately reg-ulated with steroidgenesis in the adrenal gland, ovary, and testis. In mice, adrenocorticotropic hormone increases SR-BI expression, whereas glucocorticoids suppress ex-pression in the adrenal cortex (6). In rats, luteinization of the ovary with human chorionic gondadotropin or treat-ment of granulosa cells with follicle-stimulating hormone induces expression of SR-BI and uptake of HDL choles-terol esters (7). Similarly, human chorionic gondadotro-pin stimulated SR-BI expression and uptake of DiI-labeled HDL in the testis (8). It is interesting to note that the humanSR-BI promoter contains the recognition sequence (Ad4BP)for the orphan receptor steroidogenic factor-1, which induces the expression of several genes involved in ste-roidogeneis and modulates SR-BI promoter activity in adrenal cells (9).Supraphysiological doses of a synthetic estrogen, 17␣-ethinyl estradiol, decrease hepatic expression of SR-BI in rats, suggesting a role for estrogens in modulating SR-BI expression (8). However, high-dose estrogen also in-creases hepatic LDL-receptor activity (10, 11). Therefore, decreased hepatic expression of SR-BI may have been due to elevated cholesterol content, rather than a direct effect of estrogen. Alternatively, Landschulz et al. (8) noted that hepatic and adrenal expression of SR-BI were lower in fe-male rats relative to males, suggesting that endogenous estrogens may also modulate SR-BI.Little is known concerning the hormonal regulation of SR-BII. The goal of this study was to determine if physio-logical levels of 17-estradiol modulated the levels of SR-BII. We found that 17-estradiol promoted the down-regulation of SR-BI and the up-regulation of SR-BII in HepG2 cells and in the liver of a rat estrogen replacement model. The in vivo consequences of this switch between receptors will require additional studies.Abbreviations: SR-BI/SR-BII, scavenger receptor class B type I/type II.1To whom correspondence should be addressed.e-mail: ejsmart@ by on May 16, 2007 Downloaded from1444Journal of Lipid Research Volume 42, 2001MATERIALS AND METHODSMaterialsMEM Eagles with Earle salts (phenol red minus), fetal bovineserum (non-heat inactive), l-glutamine, trypsin-EDTA, and penicillin/streptomycin were from Life Technologies, Inc.(Grand Island, NY). Percoll, 17-estradiol, PVDF membrane, and Tween 20 were from Sigma (St. Louis, MO). BioRad Dcassay was from BioRad (Hercules, CA). Rabbit serum directedagainst SR-BI and SR-BII were a generous gift from Dr. Deneysvan der Westhuyzen (UK). The SR-BI/SR-BII-blocking antibodywas generated by Quality Control Biochemicals. Horseradishperoxidase conjugated IgGs were supplied by Cappel (WestChester, PA). Super Signal® chemiluminescent substrate waspurchased from Pierce (Rockford, IL). 1␣, 2␣ (n) [3H]choles-teryl-oleate (37 Ci/mmol) was supplied by Amersham (Arling-ton Heights, IL). 125I-Na (1 mCi/ml) was purchased from NEN (Boston, MA).BuffersLysis buffer consisted of 25 mM MES (pH 6.5), 0.15 M NaCl,1% (v/v) Triton X-100, and 60 mM octylglucoside. Samplebuffer (5ϫ) consisted of 0.31 M Tris (pH 6.8), 2.5% (w/v) SDS, 50% (v/v) glycerol, and 0.125% (w/v) bromophenol blue. Tris-buffered saline (TBS) consisted of 20 mM Tris (pH 7.6) and 137 mM NaCl. Blotting buffer consisted of TBS plus 0.5% Tween 20 and 5% dry milk. Wash buffer consisted of TBS plus 0.5% Tween 20 and 0.2% dry milk. Tris-saline consisted of 50 mM Tris (pH 7.4) and 150 mM NaCl.Cell cultureHepG2 cells were cultured in a monolayer and plated in a stan-dard format. On day 0, approximately 5 ϫ 105 cells were seeded into 100-mm dishes with 10 ml of MEM eagles (phenol red minus) with Earle salts supplemented with 100 unit/ml penicillin/ streptomycin, 0.5% (v/v) l-glutamine, and 10% (v/v) fetal bovine serum (non-heat inactive). The cells were used on day 4. Isolation and labeling of lipoproteinsHDL (dϭ1.063–1.21 g/ml) was isolated from fresh human plasma by density gradient ultracentrifugation as described pre-viously (12). The HDL3 subfraction (dϭ1.13–1.18 g/ml) was iso-lated from other HDL subfractions by ultracentrifugation. HDL3 apolipoproteins were then iodinated with iodine monochloride (13) to a specific radioactivity of 400–600 cpm/ng protein. 1␣,2␣(n) [3H]cholesteryl-oleate was then incorporated into 125I-labeled HDL3 as described previously (14). The specific radio-activity of [3H]cholesterol ester in the dually labeled particles ranged from 32–35 dpm/ng cholesterol.Ligand binding and uptake assaysThe selective uptake of cholesterol esters from HDL into cellswas determined using dual-labeled HDL3 as described previously(15). Cells were grown to 90% confluency in 12 well plates, thenrinsed twice with PBS (37ЊC for uptake assays and 4ЊC for bind-ing assays). Medium containing 5% human lipoprotein-deficient serum and 10 g/ml 125I-[3H]cholesteryl-oleate-HDL was added to the cells for the indicated intervals. Following the incubation, uptake was terminated by aspirating the medium and washing the cell monolayers four times with Tris-saline (4ЊC). Cholesterol ester was extracted from the cells with 3:2 hexane–isopropanol (v/v), and the cells were solubilized in 0.6 ml of 0.5 M NaOH. The total HDL3 associated with the cells was determined by counting aliquots of the 0.5 M NaOH homogenate. The total cholesterol ester associated with the cells was determined by liquid scintilla-tion counting of the organic extracts. The amount of HDL3degraded was determined by measuring the amount of non-TCA precipitatable 125I in the cell medium. To compare cell-associated125I-HDL with [3H]cholesterol ester HDL, [3H]cholesterol esteruptake was expressed as apparent HDL protein uptake, assumingthat uptake resulted from whole HDL particle uptake as describedby Knecht and Pittman (16).Animals and treatmentsFemale Sprague-Dawley rats were housed on a 14:10 hlight:dark cycle with unrestricted access to food and water. Ratswere bilaterally ovariectomized under isoflurane anesthesia at 8 weeks of age. For 17-estradiol studies, Silastic capsules (3.8 mm diameter, 30 mm length) containing either sesame oil (control)or 17-estradiol in sesame oil (1 mg/ml) were implanted subcu-taneously at the time of surgery as previously described (17). Im-plants were replaced after 7 days and rats were killed after 14days of treatment. Organs were harvested, snap frozen on dryice, and stored at Ϫ80ЊC. Trunk blood was collected and serum harvested for determination of total cholesterol and fraction-ation by FPLC as described previously (18). Estradiol concentra-tions were determined by radioimmunoassay as described (19).All surgical procedures were approved by the University of Kentucky Institutional Animal Care and Use Committee.SDS-PAGE and immunoblottingTissues (0.1 g) were homogenized in 1.0 ml of lysis buffer witha Teflon-coated homogenizer on ice. Homogenates were incu-bated on ice for 20 min and centrifuged at 12,000 g for 15 min at4ЊC. Supernatants were collected and protein concentration de-termined by Dc assay. Proteins were diluted in 1ϫ sample bufferplus 1.2% (v/v) -mercaptoethanol and heated to 95ЊC for 5min immediately prior to loading. Proteins were separated on a12.5% polyacrylamide gel at 50 mA (constant current) and sub-sequently transferred to PVDF membrane at 50 V (constant volt-age) for 2 h. Membranes were blocked with blotting buffer for60 min at 22ЊC. Primary antibodies were diluted in blottingbuffer and incubated with blocked membranes for 60 min at22ЊC. Membranes were washed four times for 10 min in wash buffer. Horseradish peroxidase conjugated IgGs directed againstthe appropriate host IgGs were diluted and incubated with mem-branes as described for primary antibodies. Membranes were washed four times for 10 min in wash buffer and visualized using chemoluminescence. The relative signal intensities were deter-mined by densitometry. Increasing amounts of a single samplewere analyzed to verify that signal intensity varied linearly withprotein loading.Nuclease protection assayRat liver total RNA was used to reverse transcribe 120 nucleo-tide fragments corresponding to the C-terminal regions of SR-BIor SR-BII. The C-terminal regions of SR-BI and SR-BII are unique. An RNA Polymerase Promoter Addition Kit, Ribonu-clease Protection Assay Kit, and Nonisotopic Detection Kit from Ambion, Inc., were used to conduct the nuclease protection assay. The assay was performed according to the manufacturer’s instructions.RESULTS17-Estradiol alters the expression ofSR-BI and SR-BII in HepG2 cellsWe first determined if HepG2 cells contained SR-BI and/or SR-BII by immunoblotting cell lysates with SR-BI andSR-BII specific antibodies (4). Figure 1 demonstrates thatby on May 16, 2007Downloaded fromGraf, Roswell, and Smart17-Estradiol regulation of SR-BII14451446Journal of Lipid Research Volume 42, 2001HepG2 cells contained immunodetectable levels of SR-BI but not SR-BII. However, SR-BI and SR-BII were detected in cell lysates prepared from CHO cells transfected with either SR-BI or SR-BII.We next determined if HepG2 cells were capable of SR-BI-dependent selective cholesterol ester uptake. HDL par-ticles, dually labeled with [ 3 H]cholesterol ester and 125 I-apoprotein, were incubated with HepG2 cells ( Fig. 2 ) orwith HepG2 cells in the presence of 50 g/ml of SR-BI/SR-BII blocking antibody (Fig. 2) for the indicated times and the amount of selective cholesterol ester uptake de-termined. HepG2 cells selectively internalized a relatively large amount of cholesterol ester. The selective uptake of cholesterol ester was abolished in the presence of a SR-BI/SR-BII blocking antibody. Non-specific IgG did not affect the selective uptake of cholesterol ester (data not shown). Less than 0.3% of the total added radio-labeled HDL particles were degraded during the time course of the experiment.To determine the effect of 17  -estradiol on SR-BI and SR-BII expression, HepG2 cells were cultured in 10 pM 17  -estradiol for the indicated times (phenol red minus medium). At the end of the incubation, cell lysates were generated, resolved by SDS-PAGE and immunoblotted with SR-BI- and SR-BII-specific antibodies ( Fig. 3 ). 17  -Estradiol induced a time-dependent decrease in SR-BI levels and increase in SR-BII levels. SR-BI was completely down-regulated by 12 h and SR-BII was maximally up-regulated by 20 h of 17  -estradiol treatment. Quantification mea-surements done with an antibody that recognizes both SR-BI and SR-BII (4) demonstrated that SR-BII was increased 3.2-fold more than the starting level of SR-BI (data not shown).We next determined if the alterations in SR-BI and SR-BII levels affected the ability of HDL to associate with HepG2cells. Cells were incubated with 10 pM 17  -estradiol for the indicated times. The cells were then chilled to 4 Њ C and incubated with 125 I-HDL for 60 min. The cells were washed and processed to determine the extent of 125 I-HDL cell association and degradation. Figure 4A demonstrates that the amount of associated 125 I-HDL declines for the first 8 h of 17  -estradiol treatment. After 20 h of 17  -estradiol treatment the extent of 125 I-HDL that associated with the cells was approximately 3-fold greater than un-treated cells. Less than 0.3% of the total added radio-labeled HDL particles were degraded during the course of the experiment.To determine if alterations in SR-BI and SR-BII levels af-fected the ability of HepG2 cells to take up cholesterol ester selectively, cells were incubated with 10 pM 17 -estradiol forFig.1.HepG2 cells express SR-BI but not SR-BII. HepG2 cells were cultured for four days, then collected, and a cell lysate gener-ated. 20 g of protein was resolved by SDS-PAGE and transferred to nylon. As controls for SR-BI and SR-BII, 1 g of cell lysate protein generated from CHO cells transfected with SR-BI or transfected with SR-BII were also resolved by SDS-PAGE and transferred to nylon. SR-BI and SR-BII specific antiserum (4) were used to probe the membranes. The immunoblots were developed by the method of chemoluminescence (30 s exposures). Longer exposure times (20 min) did not allow the detection of SR-BII in HepG2 cells (data not shown). The data are representative of three independentexperiments.Fig.2.HepG2 cells selectively internalize cholesterol ester in a SR-BI-dependent manner. HepG2 cells (᭹) or HepG2 cells plus 50 g/ml of SR-BI/SR-BII blocking antibody () were incubated with 10 g/ml of 125I and [3H]cholesterol ester labeled HDL for the indicated times. The cells were then washed and the amount of cell associated 125I-HDL determined with a gamma counter, and the amount of [3H]cholesterol ester quantified with a beta counter. Se-lective uptake was determined by subtracting the values obtained for 125I from the values obtained for the [3H]cholesterol ester (CE). Less than 0.3% of the total added radiolabeled HDL particles were degraded during the course of the experiment. The data are from four independent experiments, mean Ϯ S.E.M, n ϭ3.Fig.3.17-Estradiol down-regulates SR-BI and up-regulates SR-BII in HepG2 cells. HepG2 cells were cultured for four days and then incubated for the indicated times (hours) with 10 pM 17-estradiol. At the end of the incubation, cell lysates were generated and 20 g of protein was resolved by SDS-PAGE, transferred to ny-lon and immunoblotted with SR-BI and SR-BII antiserum. The im-munoblots were developed by the method of chemoluminescence (30 s exposures). Longer exposure times (20 min) did not signifi-cantly alter the data (data not shown). The data are representative of five independent experiments.by on May 16, 2007Downloaded fromGraf, Roswell, and Smart 17  -Estradiol regulation of SR-BII 1447the indicated times (Fig. 4B). Three hours before each mea-surement, 10 g/ml of dually radiolabeled HDL was added to the cells. At the indicated times the cells were processed to determine the extent of selective cholesterol ester uptake.The amount of selective cholesterol ester internalized ini-tially decreased with minimal uptake occurring at 9 h of 17  -estradiol treatment. After 24 h of 17  -estradiol treatment the amount of cholesterol ester internalized was approximately 75% of that obtained in the absence of 17  -estradiol.The effect of 17  -estradiol on the expression of SR-BI and SR-BII in rat liverTo determine if 17  -estradiol influences the expression of SR-BII in vivo, we used an established rat estrogen re-placement model (17). Twelve rats were ovariectomized on day 0 of the study and immediately given implants con-taining either 17 -estradiol in sesame oil or vehicle only.Proestrus estradiol concentrations in intact cycling rats range from 40 to 80 pg/ml (20). The mean serum estra-diol concentration in the ovariectomized rats was 6.9 Ϯ0.5 pg/ml. Estrogen replacement increased estradiol con-centrations to 97.7 Ϯ 7.4 pg/ml. Four male rats and four intact cycling female rats were also studied for compari-son. On day 14 the animals were sacrificed, and the livers and the adrenal glands were harvested and immunoblot-ted with SR-BI- and SR-BII-specific antibodies. Figure 5demonstrates that none of the treatments altered the amount of SR-BI and SR-BII associated with adrenal glands. However, the experimental groups had different amounts of SR-BI and SR-BII associated with the livers.Livers from male rats and ovariectomized female rats con-tained predominantly SR-BI and a small amount of SR-BII. In contrast, livers from intact cycling female rats and ovariectomized rats receiving estrogen replacement had significantly less SR-BI and a dramatic increase in the amount of SR-BII. Because different antibodies were used to detect SR-BI and SR-BII, it is not possible to compare the relative mass amounts of SR-BI to SR-BII in Fig. 5.To determine if the changes in hepatic SR-BI and SR-BII protein levels correlated with changes in mRNA levels,total RNA was isolated from hepatic tissues and the rela-tive levels of SR-BI and SR-BII message quantified by a ri-bonuclease protection assay (Fig. 6). C-terminal specific nucleotide fragments were used so that SR-BI and SR-BIIcould be distinguished. In parallel, expression of GAPDHFig.4.The effects of 17-estradiol on HDL cell association and selective cholesterol ester uptake. HepG2 cells were cultured for four days and then incubated for the indicated times with 10 pM 17-estradiol. A: At the indicated times of 17-estradiol treatment,the cells were chilled to 4ЊC and then incubated with 10 g/ml of dually radiolabeled HDL for 1 h. The cells were washed and pro-cessed to determine the extent of HDL cell association and degra-dation. Radiolabeled HDL-binding was prevented with 50-fold ex-cess unlabeled HDL or in the presence of 50 g/ml blocking antibody (data not shown). The data are from six independent ex-periments, mean Ϯ S.E.M, n ϭ 3. B: Three hours before the indi-cated times of 17-estradiol treatment, 10 g/ml of dually radio-labeled HDL was added (2, 6, 10, 14, 21 h respectively). At the indicated times of 17-estradiol treatment, the cells were then washed and the amount of cell associated 125I-HDL determined with a gamma counter, and the amount of [3H]cholesterol ester quantified with a beta counter. Selective uptake was determined by subtracting the values obtained for 125I from the values obtained for the [3H]cholesterol ester (CE). Less than 0.3% of the total added radiolabeled HDL particles were degraded during the course of the experiment. Selective cholesterol ester uptake was inhibited with 50-fold excess unlabeled HDL or in the presence of 50 g/ml blocking antibody (data not shown). The data are from six inde-pendent experiments, means Ϯ S.E.M, n ϭ3.Fig.5.Effects of ovariectomy and ovariectomy with estrogen re-placement on the levels of liver SR-BI and SR-BII protein. Livers and adrenals from male rats, intact cycling female rats, and ovari-ectomized rats receiving a subcutaneous Silastic implant containing sesame oil or 17-estradiol (1 mg/ml) for 14 days were harvested.Cell lysates were generated and resolved by SDS-PAGE, transferred to nylon, and immunoblotted with SR-BI and SR-BII specific anti-serum. 45 g of liver lysate and 10 g of adrenal lysate were used.The immunoblots were developed by the method of chemolumi-nescence (60-sec exposures). Data from one animal in each experi-mental group is shown. All of the animals had nearly identical SR-BI and SR-BII profiles. Ovx, ovariectomy; E, 17-estradiol.by on May 16, 2007Downloaded from1448Journal of Lipid Research Volume 42, 2001was determined to validate equality of RNA loading. The relative abundance of SR-BI and SR-BII mRNA did not change in the presence of 17-estradiol.DISCUSSIONSR-BI and SR-BII are two isoforms of a class B scavenger receptor that differ only in the C-terminal cytoplasmic tail (4, 5). Estrogen has been reported to induce the down-regulation of hepatic SR-BI (8, 21). In the present study we demonstrated that as little as 10 pM of 17-estradiol could induce the complete loss of SR-BI and the dramatic up-regulation of SR-BII in HepG2 cells, a liver-derived cell line. Significantly, the amount of SR-BI and SR-BII corre-lated with the extent of 125I-HDL that associated with the cells. The 17-estradiol-induced switch from SR-BI to SR-BII did not inhibit selective cholesterol ester uptake al-though uptake did decrease by approximately 25%. Simi-lar to other studies we observed less SR-BI in intact cycling female rats compared with male rats (8). However, we re-port for the first time that intact cycling female rats contain considerably more SR-BII than male rats. Ovariectomized female rats contained as much SR-BI as male rats and down-regulated SR-BII to levels comparable to male rats.Ovariectomized female rats receiving estrogen replace-ment contained SR-BI and SR-BII protein levels compara-ble to intact cycling females.The functions of SR-BI and SR-BII have been studied in transfected cell lines. SR-BI and SR-BII both bind HDL with similar affinities and both receptors mediate the se-lective uptake of cholesterol ester from HDL (4). How-ever, SR-BII is much less efficient at selectively internaliz-ing HDL-derived cholesterol ester (4). Webb et al. (4)have estimated that SR-BII is approximately 4-fold less effi-cient at selective uptake than SR-BI. This estimate of SR-BII efficiency matches well with our current data. If SR-BII is 4-fold less efficient than SR-BI than a 4-fold increase in SR-BII would be required to obtained the same efficiency of selective cholesterol ester uptake. The final amount of 17-estradiol induced SR-BII up-regulation in HepG2cells was about 3-fold more than the starting SR-BI levels.Significantly, the amount of HDL-derived cholesterol ester internalized in 3 h was 75% of that obtained by SR-BI.The mechanism by which class B scavenger receptors mediate the selective uptake of HDL-derived cholesterol ester is not understood. SR-BI and SR-BII are identical at the amino acid level with the exception of the C-terminal cytosolic tail. Both proteins are enriched in caveolae in transfected CHO cells (4, 22) and both proteins are acylated (4, 22). The extracellular domain and C-terminal cytosolic tail of SR-BI have been postulated to be critical domains involved in selective uptake (23). How the C-terminal cytosolic tail of SR-BII decreases the efficiency of selective cholesterol ester uptake is not known. One possibility is that the cytoplasmic tail of SR-BII interacts with a cellular protein that regulates selective uptake. This speculative mechanism has not been tested.We have demonstrated that 17-estradiol induces the loss of SR-BI and the accumulation of SR-BII in HepG2cells. These observations confirm previous reports of an estrogen-induced decline in hepatic SR-BI expression and are the first to demonstrate an estrogen-induced up-regulation of SR-BII. The mechanism of how 17-estradiol causes a switch from SR-BI to SR-BII is unclear. SR-BI and SR-BII are encoded by the same gene (5). The precursor mRNA is alternatively spliced such that a 129-nucleotide exon is either included or removed to yield SR-BI or SR-BII transcripts (5). Previous studies with adrenocorticotropic hormone demonstrated that this hormone did not regulate alternative splicing. The data presented here suggest that 17-estradiol may regulate the splicing of the SR-BI/SR-BII transcript, however, RNase protection experiments did not detect significant changes in the amount of SR-BI and SR-BII specific transcripts. Alternatively, 17-estradiol may affect the stability of the proteins. Both apoAI and apoE can be post-transcriptionally modified in an estrogen-dependent process (24). Indeed, apoE mRNA shifts to the fast translating poly-somal pool in response to estrogen treatment (25).In conclusion, the data demonstrate that 17-estradiol can induce the down-regulation of SR-BI and the up-regulation of SR-BII in HepG2 cells. Despite the lower efficiency of SR-BII in selective cholesterol ester uptake, the large in-crease in SR-BII allowed the cells to internalize about 75%of the cholesterol ester that SR-BI internalized in 3 h. We have provided data demonstrating that in a rat estrogen replacement model SR-BII is up-regulated and SR-BI is down-regulated in the liver. This in vivo model will allowfuture studies to examine the impact of 17-estradiol on the metabolism of HDL.This work was supported by NIH grants HL62844, HL58475,HL64056 (EJ S), and P20RR15592 (Wise). We thank Dr. WiseFig.6.Effects of ovariectomy and ovariectomy with estrogen re-placement on the levels of liver SR-BI and SR-BII mRNA. Fifty mi-crograms of total RNA from male rats (Male), intact cycling female rats (Intact), and ovariectomized rats receiving a subcutaneous Si-lastic implant containing sesame oil (Ovx) or 17-estradiol (Ovx ϩE 2) (1 mg/ml) for 14 days were hybridized with an antisense 120nucleotide fragment of SR-BI or SR-BII and digested with RNAse A/T1. Adrenal RNA (Ad) (25 g) was used as a positive control for SR-BI and SR-BII. The antisense fragment of SR-BI or SR-BII in the absence of cellular RNA was also included with (ϩ) or without (Ϫ)treatment with RNAse A/T1. In parallel, levels of GADPH mRNA were determined to verify equal loading.by on May 16, 2007 Downloaded fromand the Atherosclerosis Research Group for invaluable advice and assistance.Manuscript received 20 February 2001 and in revised form 1 May 2001.REFERENCES1.Trigatti, B., A. Rigotti, and M. Krieger. 2000. The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism. Curr Opin Cell Biol.11: 123–131.2.Glass, C., R. C. Pittman, M. Civen, and D. Steinberg. 1985. Uptakeof high-density lipoprotein-associated apoprotein A-I and choles-terol esters by 16 tissues of the rat in vivo and by adrenal cells and hepatocytes in vitro. J. Biol. Chem.260: 744–750.3.Johnson, W. J., F. H. Mahlberg, G. H. Rothblat, and M. C. Phillips.1991. Cholesterol transport between cells and high-density lipo-proteins. Biochim. Biophys. Acta.1085: 273–298.4.Webb, N. R., P. M. Connell, G. A. Graf, E. J. Smart, W. J. de Villiers,F. C. de Beer, and D. R. van der Westhuyzen. 1998. SR-BII, an iso-form of the scavenger receptor BI containing an alternate cyto-plasmic tail, mediates lipid transfer between high density lipopro-tein and cells. J. Biol. Chem.273: 15241–15248.5.Webb, N. R., W. J. S. de Villiers, P. M. Connell, F. C. de Beer, andD. R. van der Westhuyzen. 1997. Alternative forms of the scavengerreceptor BI (SR-BI). J. Lipid Res.38: 1490–1495.6.Rigotti, A., E. R. Edelman, P. Seifert, S. N. Iqbal, R. B. DeMattos,R. E. Temel, M. Krieger, and D. L. Williams. 1996. Regulation by adrenocorticotropic hormone of the in vivo expression of scaven-ger receptor class B type I (SR-B1), a high density lipoprotein re-ceptor, in steroidogenic cells of the murine adrenal gland. J. Biol.Chem.271: 33545–33549.7.Reaven, E., A. Nomoto, S. Leers-Sucheta, R. Temel, D. L. Williams,and S. Azhar. 1998. Expression and microvillar localization of scav-enger receptor, class B, type I (a high density lipoprotein recep-tor) in luteinized and hormone-desensitized rat ovarian models.Endocrinology.139: 2847–2856.ndschulz, K., R. K. Pathak, A. Rigotti, M. Krieger, and H. H.Hobbs. 1996. Regulation of scavenger receptor, class B, type 1, a high density lipoprotein receptor, in liver and steroidogenic tis-sues of the rat. J. Clin. Invest.98: 984–995.9.Cao, G., C. K. Garcia, K. L. Wyne, R. A. Schultz, K. L. Parker, andH. H. Hobbs. 1997. Structure and localization of the human geneencoding SR-BI/CLA-1. J. Biol. Chem.272: 33068–33076.10.Windler, E. E., P. T. Kovanen, Y. S. Chao, M. S. Brown, R. J. Havel,and J. L. Goldstein. 1980. The estradiol-stimulated lipoprotein re-ceptor of rat liver. J. Biol. Chem.255: 10464–10471.11.Kovanen, P. T., M. S. Brown, and J. L. Goldstein. 1979. Increased bind-ing of low density lipoprotein to liver membranes from rats treated with 17 alpha-ethinyl estradiol. J. Biol. Chem.254: 11367–11373. 12.Strachan, A. F., F. C. de Beer, D. R. van der Westhuyzen, and G. A.Coetzee. 1988. Identification of three isoform patterns of human serum amyloid A proteins. Biochem. J.250: 203–207.13.Bilheimer, D. W., S. Eisenberg, and R. I. Levy. 1972. The metabo-lism of very low density lipoprotein. Biochim. Biophys. Acta.260:212–221.14.Gwynne, J. T., and D. D. Mahaffee. 1989. Rat adrenal uptake andmetabolism of high density lipoprotein cholesteryl ester. J. Biol.Chem.264: 8141–8150.15.Glass, C., R. C. Pittman, D. W. Weinstein, and D. Steinberg. 1983. Dis-sociation of tissue uptake of cholesterol from that of apoprotein A-Iof rat high density lipoproteins: selective delivery of cholesterol toliver, adrenal, and gonad. Proc. Natl. Acad. Sci. USA.80: 5435–5439.16.Knecht, T. P., and R. C. Pittman. 1989. A plasma membrane poolof cholesteryl esters that may mediate the selective uptake of cho-lesteryl esters from high density lipoproteins. Biochim. Biophys.Acta.1002: 365–375.17.Wise, P. M., P. Camp-Grossman, and C. A. Barraclough. 1981. Ef-fects of estradiol and progesterone on plasma gonadotropins, pro-lactin, and LHRH in specific brain areas of ovariectomized rats.Biol. Reprod.24: 820–830.18.Daugherty, A., E. Puré, D. Delfel-Butteiger, S. Chen, J. Leferovich,S. E. Roselaar, and D. J. Rader. 1997. The effects of total lympho-cyte deficiency on the extent of atherosclerosis in apolipoproteinEϪ/Ϫ mice. J. Clin. Invest.100: 1575–1580.19.Dubal, D. B., M. L. Kashon, L. C. Pettigrew, J. M. Ren, S. P. Fink-lestein, S. W. Rau, and P. M. Wise. 1998. Estradiol protects againstischemic injury. J. Cereb. Blood Flow Metab.18: 1253–1258.20.Smith, M. S., M. E. Freeman, and J. D. Neill. 1975. The control ofprogesterone secretion during the estrous cycle and earlypseudopregnancy in the rat: prolactin, gonadotropin and steroidlevels associated with rescue of the corpus luteum of pseudopreg-nancy. Endocrinology.96: 219–226.21.Fluiter, K., D. R. van der Westhuyzen, and T. J. C. van Berkel. 1998.In vivo regulation of scavenger receptor BI and the selective up-take of high density lipoprotein cholesteryl esters in rat liver pa-renchymal and kupffer cells. J. Biol. Chem.273: 8434–8438.22.Babitt, J., B. Trigatti, A. Rigotti, E. J. Smart, R. G. Anderson, S. Xu,and M. Krieger. 1997. Murine SR-BI, a high density lipoprotein re-ceptor that mediates selective lipid uptake, is N-glycosylated andfatty acylated and colocalizes with plasma membrane caveolae. J.Biol. Chem.272: 13242–13249.23.Connelly, M. A., S. M. Klein, S. Azhar, N. A. Abumrad, and D. L.Williams. 1999. Comparsion of class B scavenger receptors, CD36and scavenger receptor BI (SR-BI), shows that both receptorsmediate high density lipoprotein-cholesteryl ester selective uptakebut SR-BI exhibits a unique enhancement of cholesteryl ester up-take. J. Biol. Chem.274: 41–47.24.Srivastava, R. A., E. S. Krul, R. C. Lin, and G. Schonfeld. 1997. Reg-ulation of lipoprotein metabolism by estrogen in inbred strains ofmice occurs primarily by posttranscriptional mechanisms. Mol. CellBiochem.173: 161–168.25.Srivastava, R. A., N. Srivastava, M. Averna, R. C. Lin, K. S. Korach,D. B. Lubahn, and G. Schonfeld. 1997. Estrogen up-regulates apoli-poprotein E (ApoE) gene expression by increasing ApoE mRNAin the translating pool via the estrogen receptor alpha-mediatedpathway. J. Biol. Chem.272: 33360–33366.by on May 16, 2007Downloaded fromGraf, Roswell, and Smart17-Estradiol regulation of SR-BII1449。